Zhejiang Lanyu Digital Technology
301585
BBK Test Systems
301598
MEIZHIGAO
834765
Youkeshu Technology
300209
Hangzhou Raycloud Technology Co.,Ltd
688365
CN Stock MarketDetailed Quotes
600521 Zhejiang Huahai Pharmaceutical
- 19.04
- +0.39+2.09%
Not Open Dec 20 15:00 CST
27.93BMarket Cap24.50P/E (TTM)
19.17High18.58Low129.67KlotVolume18.73Open18.65Pre Close246.21MTurnover0.88%Turnover Ratio33.64P/E (Static)1.47BShares21.5552wk High3.27P/B27.93BFloat Cap10.5152wk Low20.52Limit Up1.47BShs Float44.96Historical High16.79Limit Down3.16%Amplitude-0.52Historical Low0.20Dividend TTM18.99Avg Price54.86KlotAsk1.05%Div YieldTTM100Lot Size69.07KlotBid
Zhejiang Huahai Pharmaceutical News
Zhejiang Huahai Pharmaceutical (600521): The integration of Active Pharmaceutical Ingredient and formulation is a leading player, with its Global layout accelerating.
Investment highlights: The Active Pharmaceutical Ingredient Industry is at the upward phase of its cycle, and under multiple catalysts, long-term growth potential is expected to be unlocked. In 2023, the domestic Active Pharmaceutical Ingredient industry experienced high baselines due to orders related to the pandemic in 2022, as well as downstream formulation manufacturers digesting stock accumulated during the pandemic.
Chinese Drug Regulator Accepts Huahai Pharma Unit's Application for Adalimumab Injection
Huahai Pharmaceutical's Two Drugs Secures Spot in China's National Drug Procurement Program
Express News | The opening of the tenth batch of national Pharmaceutical centralized purchasing has prompted nearly 30 listed companies to announce their products are likely to be selected after the market close.
Zhejiang Huahai Pharmaceutical (600521.SH): Products are expected to be selected for the tenth batch of national pharmaceutical centralized procurement.
On December 13, Gelonghui reported that Zhejiang Huahai Pharmaceutical (600521.SH) announced that on December 12, 2024, the company participated in the bidding for the 10th batch of national drug centralized procurement organized by the National Joint Procurement Office, and the company products Apsaglerone Tablets and Sitagliptin Metformin Tablets (II) are expected to be selected for this centralized procurement.
Express News | Zhejiang Huahai Pharmaceutical: The subsidiary's application for上市许可for the pharmaceutical Adalimumab injection has been accepted.
Express News | The latest bid price for Sitagliptin tablets in collective procurement has dropped to below 0.2 yuan per tablet, a decline of over 90%.
Zhejiang Huahai Pharmaceutical Gets China Nod for Type 2 Diabetes Drug
Huahai Pharmaceutical Gets Nod to Register Dapagliflozin Tablets
Express News | Zhejiang Huahai Pharmaceutical: The first subject in New Zealand to be dosed with the TSLP/IL-11 bispecific monoclonal antibody independently developed by its subsidiary.
Research reports focus | China Merchants Securities: zhejiang huahai pharmaceutical Q3 profit ability significantly improved, maintaining a "strong recommendation" rating
China Merchants Research Reports pointed out that Zhejiang Huahai Pharmaceutical (600521.SH) Q3 overall performance is close to the upper limit of the forecast, with significantly improved profitability. It is expected that the company's active pharmaceutical ingredient and formulation product structure will continue to adjust, the proportion of new products will increase, and the manifestation of lean management, economies of scale, and the effectiveness of technological transformation will drive a significant increase in profit margin. Since the beginning of this year, several of the company's products have entered key clinical stages. Zhejiang Huahai Pharmaceutical is a leading domestic integrated company in active pharmaceutical ingredients and formulations, with the turning point for active pharmaceutical ingredients and generic drug formulations trending upward, the profitability is expected to continue to improve. Innovative drugs are gradually entering the harvest period, and innovative assets are exp
Zhejiang Huahai Pharmaceutical Gets China Nod for Anti-Tumor Injection
Zhejiang Huahai Pharmaceutical (600521): Performance close to the upper limit of the forecast, highlighting the resilience of the industry leader.
In the first three quarters of 2024, zhejiang huahai pharmaceutical achieved a revenue of 7.248 billion yuan, an increase of 16.76% year-on-year; net income attributable to shareholders was 1.031 billion yuan, an increase of 42.92% year-on-year; net income attributable to shareholders after deducting non-recurring gains and losses was 1.033 billion yuan, an increase of +.
Express News | Zhejiang Huahai Pharmaceutical: Obtained the pharmaceutical registration certificate for methotrexate injection.
Subsidiary's slow research and development progress questioned, zhejiang huahai pharmaceutical responded: "More than 10 products have entered the clinical research stage" | Direct hit on earnings conference
①At the earnings conference, zhejiang huahai pharmaceutical's research and development pipeline progress was questioned by investors, to which the company's secretary to the board, Zhu Yonghua, introduced the situation of the ongoing pipeline. ②On the zhejiang huahai pharmaceutical side, influenced by factors such as growth in original research big clients, revenue from active pharmaceutical ingredient and formulation business has increased in the first three quarters of this year.
gf sec: The upstream prices of penicillin and cephalosporin are fluctuating at high levels, while the active pharmaceutical ingredient is stabilizing at a low point.
According to data from the National Bureau of Statistics, the year-on-year PPI value for the manufacturing of active pharmaceutical ingredients in September 2024 is 97.10, an increase of 2.0 compared to the previous month, and up 1.63 from the average of 95.47 in the first half of 2024. Since the year-on-year PPI for active pharmaceutical ingredient manufacturing fell below 100 in the entire year of 2023, the recent PPI values have been on the rise, indicating that the overall price of active pharmaceutical ingredients is in a slight recovery phase after reaching a low.
Pacific Securities: Q3 revenue and profit growth of the active pharmaceutical ingredient sector have accelerated significantly, bullish on the high growth trend in Q4 performance.
In Q1 2024, the sector's gross margin is 36.38%, with a net margin of 12.78%. Q2 gross margin is 37.21%, with a net margin of 15.52%. Q3 gross margin is 38.27%, +1.88pct year-on-year, +1.06pct quarter-on-quarter, and net margin is 14.07%, +3.98pct year-on-year, -1.45pct quarter-on-quarter. Both gross margin and net margin have reached a new high compared to the same period in the past three years.
Express News | Zhejiang Huahai Pharmaceutical: Obtained the registration certificate for linagliptin and metformin hydrochloride tablets
Zhejiang Huahai Pharmaceutical (600521): Improved Profitability Promotes Innovative Pipeline
Report Summary: Quality improvement and efficiency enhancement, profitability improved under lean transformation, and innovation pipeline gradually advancing. Investment Highlights: Maintain a "shareholding" rating. The company released the third quarter performance report, with a revenue of 7.248 billion yuan in 2024Q1-Q3 (+16).
Zhejiang Huahai Pharmaceutical (600521) third quarter report review in 2024: Performance meets expectations, steady progress leads to long-term success.
On October 30th, the company released its third-quarter report. In the first three quarters of 2024, the company achieved revenue of 7.248 billion yuan (+16.76%) and net income attributable to the parent company of 1.031 billion yuan (+42.92%).
